Trastuzumab, a recombinant humanized monoclonal antibody that binds to the extracellular subdomain IV of HER2, is the first anti-HER2 agent approved for the treatment of HER2-positive metastatic and early BC [5,6,7]. This evidence concerns the gene ERBB2 and breast cancer.